Metastatic Melanoma
Conditions
Brief summary
To determine the feasibility and safety of administering a regimen of TIL/IL-2, using a cell product manufactured in the Yale Advanced Cell Therapy Laboratories, in subjects with metastatic melanoma who are not responding or have progressed after receiving prior therapy with a PD-1/PD-L1 antagonist used alone or in combination with anti-CTLA-4. Additionally, a second cohort of patients with metastatic melanoma who are not responding or have progressed after receiving prior therapy with a PD-1/PD-L1 antagonist alone or in combination with anti-CTLA-4 will receive anti-PD-1 and anti-CTLA-4 therapy with Nivolumab and Ipilimumab.
Detailed description
The objectives of this study have been expanded since its original registration to inlcude an additional cohort of patients (now designated Cohort 1 and Cohort 2). Cohort 1 is the original group of patients described in the initial registration of the study. Cohort 1 Objectives: * To determine the feasibility and safety of administering a regimen of TIL/IL-2, using a cell product manufactured in the Yale Advanced Cell Therapy Laboratories, in subjects with metastatic melanoma who are not responding or have progressed after receiving prior therapy with a PD-1/PD-L1 antagonist used alone or in combination with anti-CTLA-4. * To assess for evidence of clinical activity. * To conduct a preliminary assessment of the TCR clonotypes present in marker positive CD8+ cells (4-1BB, LAG-3, TIM-3, PD-1) versus marker-negative CD8+ T-cells early in the expansion cultures and compare to clonotypes late in the final product and in peripheral blood lymphocytes (PBL) 1 and 2 months post infusion. Cohort 2 Objectives: * To determine the feasibility and safety of administering a regimen of TIL/IL-2, using a cell product manufactured in the Yale Advanced Cell Therapy Laboratories, followed by anti-PD-1 and anti-CTLA-4 therapy with Nivolumab and Ipilimumab in subjects with metastatic melanoma who are not responding or have progressed after receiving prior therapy with a PD-1/PD-L1 antagonist alone or in combination with anti-CTLA-4. * To evaluate the efficacy of TIL/IL-2 therapy in combination with subsequent anti-PD-1 Nivolumab and anti-CTLA-4 Ipilimumab by assessing the objective response rate by immune-related RECIST (irRECIST). * To conduct a preliminary assessment of the TCR clonotypes present in marker positive CD8+ cells (e.g. 4-1BB, LAG-3, TIM-3, PD-1) versus marker-negative CD8+ T-cells early in the expansion cultures and compare to clonotypes late in the final product and in peripheral blood lymphocytes (PBL) 1 and 2 months post infusion.
Interventions
The regimen consists of treatment with cyclophosphamide and fludarabine,followed by infusion of up to 3x1011 lymphocytes (minimum of 1x109) expanded in vitro from subjects own resected tumor followed by the administration of aldesleukin (IL-2).
• Within 1 week post discharge subjects will be treated with Nivolumab 1 mg/kg and Ipilimumab 3 mg/kg every 3 weeks for 4 doses. Following this, patients will receive Nivolumab 480 mg every 4 weeks. Adjuvant Nivolumab will continue until evidence of disease progression or inability to tolerate treatment.
Sponsors
Yale University
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Intervention model description
2 separate cohorts are included in the study design. These groups will not be directly compared.
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
For Cohorts 1 and 2: * Metastatic melanoma; * A metastatic lesion at least 1.5 cm in diameter that can be removed surgically * Measurable or evaluable disease not including the resected lesion * ECOG PS of 0 or 1 prior to cell harvest * Assessment by the treating physician that ECOG performance status of no higher than 2 can be maintained at least for the period of cell generation, lymphoablation, cell infusion and IL-2 administration (for at least 6 weeks following cell harvest) * Tumor refractory to or progressing following prior PD-1/PD-L1 therapy alone or in combination with an anti-CTLA-4 agent * Ability to understand risks and benefits of the treatment and to give informed consent
Exclusion criteria
For Cohorts 1 and 2: * Received prior cell transfer therapy that included non-myeloablative or ablative chemotherapy * Any significant major organ dysfunction (see protocol) * Residual toxicity \> gr1 from immune checkpoint inhibitor other than persistent endocrinopathy on hormone replacement; all symptoms of prior colitis and enteritis must have resolved completely as assessed by history * Any contraindication to neutropenia or thrombocytopenia for up to 2 weeks (no active major infection, no site of active, clinically significant bleeding) * Concurrent major medical illnesses * Any form of immunodeficiency * Requirement for steroids \> 10 mg prednisone daily or equivalent * Severe hypersensitivity to any of the agents used in this study * Contraindications for IL-2 administration At the time of lymphoablation subjects must meet baseline eligibility criteria with the following additions and exceptions: • Confirmation by lab that cell product can be ready for harvest and infusion within 7 days For Cohort 2 only: At the time of the start of anti-PD-1/anti-CTLA-4 therapy, subjects must meet baseline eligibility criteria with the following additions and exceptions: * Patient cannot have a steroid requirement \> 10 mg prednisone daily or equivalent * Patients who have received prior PD-1/PD-L1 antagonist therapy and developed severe autoimmune disease precluding further immune checkpoint therapy * Any organ dysfunction that makes the subject ineligible for anti-PD1 and anti-CTLA-4 treatment as deemed by the treating investigator * ECOG PS of 0-2 * Hgb of at least 8.0 gm/dl (may be transfused to this level) * Creatinine not greater than 2.5 mg/dl * AST or ALT not \> 5x ULN and total bilirubin not \> 2.5 mg/dl * No clinically significant change in major organ function compared to initial eligibility evaluation * Prior to initiating the lymphoablation regimen, there can be no untreated brain lesion \> 1.0 cm, and/or with significant evidence of hemorrhage. Subjects may begin lymphoablation no less than 1 full day after completing WBRT or stereotactic radiotherapy for brain lesions.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Events | up to 12 months | To determine the safety of administering a regimen of TIL/IL-2, incidence of drug-related adverse events (AEs) will be summarized across adverse event type in terms of frequency by event type. |
| Serious Adverse Events | up to 12 months | To determine the safety of administering a regimen of TIL/IL-2, serious adverse events (SAEs) will be summarized across event type in terms of frequency by event type. SAE's will include events leading to discontinuation, deaths and clinical laboratory test abnormalities |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate to TIL | up to 12 months | Objective response rate (ORR) of the TIL/IL-2 regimen based on investigator review of radiographic images using RECIST 1.1 criteria |
Other
| Measure | Time frame | Description |
|---|---|---|
| Assessment of Immune features of TIL: 4-1BB | up to 12 months | to conduct a preliminary assessment of TCR clonotypes using deep sequencing of TCRs from the cell product and of immunologic markers present in marker positive CD8+ cells (specifically 4-1BB, LAG-3, TIM-3, PD-1) |
| Assessment of Immune features of TIL: PD-1 | up to 12 months | to conduct a preliminary assessment of TCR clonotypes using deep sequencing of TCRs from the cell product and of immunologic markers present in marker positive CD8+ cells (specifically 4-1BB, LAG-3, TIM-3, PD-1) |
| Assessment of Immune features of TIL: LAG-3 | up to 12 months | to conduct a preliminary assessment of TCR clonotypes using deep sequencing of TCRs from the cell product and of immunologic markers present in marker positive CD8+ cells (specifically 4-1BB, LAG-3, TIM-3, PD-1) |
| Assessment of Immune features of TIL: TIM-3 | up to 12 months | to conduct a preliminary assessment of TCR clonotypes using deep sequencing of TCRs from the cell product and of immunologic markers present in marker positive CD8+ cells (specifically 4-1BB, LAG-3, TIM-3, PD-1) |
Countries
United States
Outcome results
None listed